logo
  

TAL Education Q3 Loss Narrows, But Revenue Shrinks

TAL Education Group (TAL), a Chinese education solutions provider, on Thursday reported a narrower loss for the third-quarter on sharply lower operating expenses. However, it reported a fall in revenue, amidst exchange rate fluctuations and seasonality.

Alex Peng, TAL's Chief Financial Officer, said: "Although the revenue of this quarter was affected by exchange rate fluctuations and seasonality, our new business has maintained the momentum of continuous development…"

For the three-month period to November 30, the Beijing-headquartered firm recorded a loss of $51.6 million or $0.24 per share, compared with a loss of $99.4 million or $0.46 per share of a year ago.

The lower loss reflected sharp decline in operating expenses, particularly cost of revenue as well as selling and marketing expenses.

Operating costs and expenses were at $266.3 million, compared with $1.139 billion in the third quarter of 2022. Cost of revenues also moved down to $103 million from $519.5 million of last year.

Selling and marketing expenses stood at $70.4 million, compared with $273.6 million, reported for the third quarter of 2022.

Loss per ADS fell to $0.08 from $0.15 per ADS of previous year period.

Excluding items, loss was at $23.2 million, versus previous year's loss of $58.6 million.

On adjusted basis, loss per ADS recorded at $0.04, compared with loss of $0.09 per ADS of previous fiscal.

Loss from operations stood at $32.9 million, lesser than loss of $108.4 million of previous year quarter.

Net revenues moved down to $232.7 million from $1.020 billion reported for the third-quarter of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots. The US Food and Drug Administration has cleared cultivated chicken developed by GOOD Meat Inc., the cultivated meat division of alternative foods startup Eat Just Inc. This is FDA's second pre-market consultation for a human food made from cultured animal cells after UPSIDE Foods. GOOD Meat is now required to meet Federal requirements including approvals from the US Department of Agriculture. A group of 23 U.S. states attorneys general have asked South Korean car manufacturers Hyundai Motor and Kia Corp. to take action more quickly to solve problems with millions of U.S. vehicles facing theft. The issue is related to the companies' failure to equip vehicles with anti-theft immobilizers, which has been a standard equipment on vehicles sold by other major manufacture
RELATED NEWS
Follow RTT